Drug Profile
BAL 200
Alternative Names: BAL-200Latest Information Update: 30 Jan 2023
Price :
$50
*
At a glance
- Originator iNtRON Biotechnology
- Class Antibacterials; Endolysins
- Mechanism of Action Cell wall inhibitors; Peptidoglycan modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Anthrax; Gram-positive infections
Most Recent Events
- 25 Jan 2023 Pharmacodynamics data from a preclinical trial in Anthrax released by iNtRON Biotechnology
- 06 Jun 2022 BAL 200 is available for licensing as of 06 Jun 2022. www.intodeworld.com
- 06 Jun 2022 iNtRON Biotechnology announces intention to submit IND application to regulatory bodies for Anthrax